Literature DB >> 7341767

[The effect of an intravenous calcium load on plasma prolactin in man (author's transl)].

G Dumoulin, N U Nguyen, M T Henriet, C Mougin, S Berthelay.   

Abstract

Eighteen male volunteers, from 20 to 35 years, were studied after an overnight fast and in a resting phase. Nine of them were injected i.v. at 09.00 h with calcium (180 mg Ca in 20 ml), nine controls received the same volume of 0,9% NaCl. Plasma PRL, calcium, PTH, and urinary cyclic AMP were determined just before i.v. injection and 1, 2 and 3 hours later. In the controls, plasma PRL was decreased after the i.v. injection of 0.9% NaCl. Plasma calcium, PTH and urinary cyclic AMP levels were unchanged. In the calcium treated-group, plasma PRL, PTH and urinary cyclic AMP decreased progressively. No significant difference in plasma PRL levels was observed between the two groups. A rise in plasma calcium produced by i.v. calcium injection (+ 1 mg/100 ml 1 hour after injection), sufficient to decrease plasma PTH and urinary cyclic AMP, did not change the plasma prolactin level in man.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7341767

Source DB:  PubMed          Journal:  J Physiol (Paris)        ISSN: 0021-7948


  3 in total

1.  Thyrotropin-releasing hormone stimulation of thyrotropin secretion is suppressed by calcium ion antagonists that block transmembrane influx and intracellular mobilization of calcium ion in human subjects.

Authors:  M Yamada; M Mori; M Yamaguchi; H Akiyama; S Shiono; I Kobayashi; S Kobayashi
Journal:  J Endocrinol Invest       Date:  1986-06       Impact factor: 4.256

2.  Effect of 1,25-dihydroxyvitamin D3 on plasma prolactin in patients with renal failure on regular dialysis treatment.

Authors:  D Verbeelen; L Vanhaelst; A C Van Steirteghem; J Sennesael
Journal:  J Endocrinol Invest       Date:  1983-10       Impact factor: 4.256

3.  Effect of 1,25-dihydroxyvitamin D3 and nifedipine on prolactin release in normal man.

Authors:  D Verbeelen; L Vanhaelst; M Fuss; A C Van Steirteghem
Journal:  J Endocrinol Invest       Date:  1985-04       Impact factor: 4.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.